Efficacy of P2Y(12) receptor antagonists in patients with atrial fibrillation according to the CHA(2)DS(2)VASc score

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F16%3A00011319" target="_blank" >RIV/75010330:_____/16:00011319 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/16:43910960

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0167527316300468" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0167527316300468</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijcard.2016.01.039" target="_blank" >10.1016/j.ijcard.2016.01.039</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy of P2Y(12) receptor antagonists in patients with atrial fibrillation according to the CHA(2)DS(2)VASc score

Popis výsledku v původním jazyce

The aim of presented study was to verify whether the presence of AF impacts the efficacy of P2Y12 receptor antagonists in the group of patients after stent-PCI, and to investigate whether there is a correlation between CHA2DS2VASc score and the efficacy of P2Y12 receptor antagonists in this group of patients. The main finding of the presented study is that the presence of AF does not impact the efficacy of prasugrel or ticagrelor. For the replacement of clopidogrel one of prasugrel or ticagrelor should be considered in patients with AF who undergo stent-PCI in a setting of ACS and who are in a high risk of thrombotic events and low bleeding risk. Periprocedural administration of GP IIb/IIIa inhibitors in this high risk population increases the efficacy of clopidogrel.

Název v anglickém jazyce

Efficacy of P2Y(12) receptor antagonists in patients with atrial fibrillation according to the CHA(2)DS(2)VASc score

Popis výsledku anglicky

The aim of presented study was to verify whether the presence of AF impacts the efficacy of P2Y12 receptor antagonists in the group of patients after stent-PCI, and to investigate whether there is a correlation between CHA2DS2VASc score and the efficacy of P2Y12 receptor antagonists in this group of patients. The main finding of the presented study is that the presence of AF does not impact the efficacy of prasugrel or ticagrelor. For the replacement of clopidogrel one of prasugrel or ticagrelor should be considered in patients with AF who undergo stent-PCI in a setting of ACS and who are in a high risk of thrombotic events and low bleeding risk. Periprocedural administration of GP IIb/IIIa inhibitors in this high risk population increases the efficacy of clopidogrel.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Cardiology

ISSN

0167-5273

e-ISSN

—

Svazek periodika

207

Číslo periodika v rámci svazku

March

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

3

Strana od-do

84-86

Kód UT WoS článku

000371271400026

EID výsledku v databázi Scopus

—